SCHEMBL2711752

SCHEMBL2711752

COc1cc(F)c(-c2c3ccccc3c(-c3ccccc3)c3cccc(F)c23)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.42
CYP2C9 P11712 5/20 0.42
CYP3A4 P08684 4/20 0.42
CYP2C19 P33261 4/20 0.42
ACHE P22303 1/20 0.40
CYP2B6 P20813 2/20 0.38
VDR P11473 1/20 0.38
AHR P35869 1/20 0.38
NR1I3 Q14994 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP2E1 P05181 1/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2A6 P11509 1/20 0.38
CYP4B1 P13584 1/20 0.38
CYP3A5 P20815 1/20 0.38
CYP2A7 P20853 1/20 0.38
CYP3A7 P24462 1/20 0.38
CYP2F1 P24903 1/20 0.38
CYP2C18 P33260 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12086138 0.94 CYP1A2 (0.40) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL12086196 0.94 CYP1A2 (0.42) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL2727761 0.93 CYP1A2 (0.41) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL2712835 0.93 ACHE (0.45) ACHECA1CA2ALOX15MAPK1
SCHEMBL2710330 0.91 NFE2L2 (0.38) CYP1A2CYP2C9CYP3A4CYP2C19CYP2B6
SCHEMBL2710333 0.91 CYP1A2 (0.39) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL12086176 0.90 CYP1A2 (0.41) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL2711671 0.89 L3MBTL1 (0.34) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL2709723 0.89 CYP1A2 (0.40) CYP1A2CYP2C9CYP3A4CYP2C19ACHE
SCHEMBL2728177 0.88 ACHE (0.38) CYP1A2CYP2C9CYP3A4CYP2C19ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
EP-2445987-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS Cyalume Technologies, Inc (US) 2012-05-02 EP disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
WO-2010151654-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECHNOLOGIES, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 CYP1A2 22/4885CYP2C9 44/4885CYP3A4 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.